ASX-listed Resmed rises; Citi lifts PT on margin expansion prospect

** ASX-listed Resmed RMD.AX rises as much as 2.4% to A$41.910, highest since September 10

** Stock set for second straight week of consecutive gains, having risen 1.8% so far this week

** Citi raises PT to A$51 from A$49

** Expects healthcare tech co will expand margins further to 63% in FY27 from 60% in FY25 helped by its AirSense 11, which is used to treat sleep apnea

** Sees concerns to exist around drugs like Ozempic helping people beat obesity, a major cause of sleep apnea; fewer obese individuals could mean fewer patients needing co's devices

** Believes anecdotes suggest better sleep after Ozempic use but only small portion of market currently treated; says will take years before it becomes real threat

** Stock rated "buy" on avg; median PT is A$48.30, per data compiled by LSEG

** RMD gains ~13% YTD